C. Overshiner

发表

N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a Novel Metabotropic Glutamate 2 Potentiator with Potential Anxiolytic/Antidepressant Properties: In Vivo Profiling Suggests a Link between Behavioral and Central Nervous System Neu

G. Marek, K. Perry, J. Witkin, 2011, Journal of Pharmacology and Experimental Therapeutics.

Disinhibitory effects of LY354740, a new mGluR2 agonist, on behaviors suppressed by electric shock in rats and pigeons

J. Monn, C. Overshiner, M. Benvenga, 1999 .

The novel 5-Hydroxytryptamine(1A) antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine.

D. Wong, T. Branchek, J. Zgombick, 2000, The Journal of pharmacology and experimental therapeutics.

Novel bicyclo[3.1.0]hexane analogs as antagonists of metabotropic glutamate 2/3 receptors for the treatment of depression.

J. F. Soriano, P. Ornstein, M. Blanco, 2016, Bioorganic & medicinal chemistry letters.

The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits

S. Mitchell, J. Witkin, D. Schoepp, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Microsoft Word-67692688-file00

B. Giros, K. Perry, E. Tzavara, 2012 .

Metabotropic Glutamate Receptor

J. F. Soriano, P. Ornstein, S. Atwell, 2016 .

M1 and M2 Muscarinic Receptor Subtypes Regulate Antidepressant-Like Effects of the Rapidly Acting Antidepressant Scopolamine

R. E. Higgs, A. Nikolayev, R. Higgs, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive N-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of Depression.

P. Ornstein, V. Tolstikov, S. Mitchell, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.

J. F. Soriano, P. Ornstein, S. Atwell, 2016, Journal of medicinal chemistry.

Pharmacological profile of LY301317, a potent and selective 5‐HT1A agonist

J. Gidda, R. Fuller, S. Hemrick-Luecke, 1997 .

Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive N-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of Depression.

P. Ornstein, S. Mitchell, G. Gilmour, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine

K. Perry, F. Bymaster, E. Tzavara, 2006, Molecular Psychiatry.

Comparative Effects of LY3020371, a Potent and Selective mGlu2/3 Receptor Antagonist, and Ketamine, a Non-Competitive NMDA Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists for the Treatment of Depression

V. Tolstikov, S. Mitchell, G. Gilmour, 2017 .

M1 and M2 Muscarinic Receptor Subtypes Regulate Antidepressant-Like Effects of the Rapidly Acting Antidepressant Scopolamine

J. Witkin, J. Catlow, C. Overshiner, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Behavioral Effects of a Novel Benzofuranyl-Piperazine Serotonin-2C Receptor Agonist Suggest a Potential Therapeutic Application in the Treatment of Obsessive–Compulsive Disorder

K. Briner, Xia Li, Denise Morrow, 2017, Front. Psychiatry.